News
- 07/26/11
Calando Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board Read - 06/21/11
Calando Research to Present at Two Nanomedicine-Focused Events in London Read - 04/27/11
Calando Research Announces RNAi Leader John J. Rossi, PH.D. to Join Calando Scientific Advisory Board Read - 01/18/11
Calando Increases Investment in RNAi Subsidiary Calando Pharmaceuticals Read - 09/29/10
Calando Ceo Provides Update on Company Strategy and Milestone Achievements Read - 09/23/10
Calando Increases Ownership in RNAi Subsidiary Calando Pharmaceuticals, Inc. Read - 04/05/10
White Paper – CALAA-01 Results Show Delivery Technology to Meet Critical Need in RNAi Therapeutics, Putting Calando in Position to Monetize Asset. Read - 03/22/10
Press Release – Calando Research Subsidiary, Calando Pharmaceuticals, Provides First Proof of RNA Interference in Humans with Systemically Administered siRNA Therapeutic; Clinical Trial Results Published in Nature. Read - 03/21/10
Caltech-led Team Provides Proof in Humans of RNA Interference Using Targeted Nanoparticles. Read - 04/11/09
Press Release – Calando Subsidiary Calando Pharmaceuticals Expands Board of Directors. Read - 06/23/09
Press Release – Calando Subsidiary Calando Pharmaceuticals Enters into License Agreement with Cerulean Pharma Inc. Read - 08/12/08
Press Release – Calando Pharmaceuticals Publishes New Results of siRNA Delivery Using Its Rondel™ Technology In Sepsis. Read - 10/23/08
Press Release – Calando Pharmaceuticals Announces Completion of IT-101 Phase 1 Clinical Study. Read - 10/07/08
Press Release – Calando Patent Issues For Active Ingredient of Lead siRNA Drug Candidate. Read - 09/15/08
Press Release – Calando Pharmaceuticals Announces Next siRNA Therapeutic Candidate for Oncology. Read - 06/02/08
Press Release – Calando Pharmaceuticals Doses First Patient In siRNA Phase I Clinical Trial. Read - 05/13/08
Press Release – Calando Granted Broad Patent rights to RNAi Technology in China. Read - 04/24/08
Press Release – Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic. Read - 03/13/08
Press Release – Calando files IND for siRNA nanoparticle therapeutic in oncology. Read